ORPHAZYME RECEIVES ORPHAN DRUG DESIGNATION TO ARIMOCLOMOL FOR INCLUSION BODY MYOSITIS FROM THE U.S. FDA

Orphazyme A/S ("Orphazyme" or the "Company"), a Danish biotech company with a late stage orphan drug pipeline, today announced that the U.S. Food and Drug Administration (“FDA”), Office of Orphan Products Development, has granted an orphan drug designation to arimoclomol for the treatment of the orphan disease Inclusion Body Myositis (“IBM”).